Volume 28, Issue 2 (9-2025)
jha 2025, 28(2): 82-89 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Dehghan Tooranposhti A, Eslamitabar S, Sobhanian A. Comparative study of pharmaceutical pricing systems in Iran and selected countries. jha 2025; 28 (2) :82-89
URL: http://jha.iums.ac.ir/article-1-4592-en.html
URL: http://jha.iums.ac.ir/article-1-4592-en.html
1- Department of Pharmacy, TeMS.C., Islamic Azad University, Tehran, Iran
2- Smart Medical Sciences University, Ministry of Health, Tehran, Iran.
3- Department of Pharmacoeconomics & Pharmaceutical Management, TeMS.C., Islamic Azad University, Tehran, Iran. ,sasobhanian@yahoo.com
2- Smart Medical Sciences University, Ministry of Health, Tehran, Iran.
3- Department of Pharmacoeconomics & Pharmaceutical Management, TeMS.C., Islamic Azad University, Tehran, Iran. ,
Abstract: (37 Views)
Introduction: Drug pricing plays a crucial role in healthcare delivery, affecting patients' access to essential medicines and determining the financial sustainability of healthcare systems worldwide. High drug prices lead to inequality in access, while strict price control may discourage investment in this industry and reduce progress and innovation in medicines. The aim of this study was to compare the drug pricing system in Iran with that of selected countries including France, Turkey, and Spain.
Methods: This comparative study used printed and non-printed books and articles identified through scientific databases. The collected data were qualitatively compared.
Results: In Turkey, both foreign and domestic reference pricing systems, along with negotiations with manufacturers, serve as the main drug pricing strategies. In Spain, the pricing system combines mark-up, negotiated pricing, reference pricing, and value-based pricing. In France, negotiated and value-based pricing system are the main strategies, with reference pricing as a complementary approach. In Iran, the foreign reference pricing system, similar to the other three countries, is the basis for pricing along with manufacturer proposals, though for some drug categories, pricing is still based on cost and mark-up.
Conclusion: It seems that in Iran, as in leading countries in this industry, greater attention should be paid to value-based drug pricing.
Methods: This comparative study used printed and non-printed books and articles identified through scientific databases. The collected data were qualitatively compared.
Results: In Turkey, both foreign and domestic reference pricing systems, along with negotiations with manufacturers, serve as the main drug pricing strategies. In Spain, the pricing system combines mark-up, negotiated pricing, reference pricing, and value-based pricing. In France, negotiated and value-based pricing system are the main strategies, with reference pricing as a complementary approach. In Iran, the foreign reference pricing system, similar to the other three countries, is the basis for pricing along with manufacturer proposals, though for some drug categories, pricing is still based on cost and mark-up.
Conclusion: It seems that in Iran, as in leading countries in this industry, greater attention should be paid to value-based drug pricing.
Keywords: Healthcare systems, Drug pricing regulations, Reference pricing, Negotiated pricing, Value-based pricing
Type of Study: Short Communication |
Subject:
Health Services Management
Received: 2025/07/20 | Accepted: 2025/08/27 | Published: 2025/10/11
Received: 2025/07/20 | Accepted: 2025/08/27 | Published: 2025/10/11
References
1. Miraldo M. Reference pricing and firms' pricing strategies. Journal of Health Economics. 2009; 28(1): 176-97. [DOI:10.1016/j.jhealeco.2008.09.006]
2. Jafari M, Rezaeizadeh MJ, Abbasi B. Investigating the regulations governing the distribution and pricing of the Iranian pharmaceutical system from the perspective of the right to health. Journal of Medicine Spiritual Cultivation. 2021; 29(4): 296-301. [In Persian]. Available from: https://www.magiran.com/p2276391
3. Varmaghani M, Hashemi-Meshkini A, Abdollahiasl A, Heidari E, Zekri H-S, Yaghoubifard S, et al. An overview to pharmaceutical financing in Iran. Journal of Pharmacoeconomics and Pharmaceutical Management. 2016; 2(1-2): 45-9. Available from: https://jppm.tums.ac.ir/index.php/jppm/article/view/43
4. Howe A. Understanding pharmaceutical pricing in the United States. Economics Honors Papers. 2020; 32: 1-49. Available from: https://digitalcommons.conncoll.edu/econhp/32
5. Motevalli MH, Dowlati Beirami A, Salimi A, Yousefi N. Comparison of price regarding the domesticly produced medicine with the price of the similar generic medicine in India. Quarterly Journal of Management Strategies in Health System. 2022 Mar; 6(4): 353-62. [DOI:10.18502/mshsj.v6i4.8989]
6. Islami Tabar Sh, Iame E, Anwar F. Legal considerations of pricing in the pharmaceutical industry in Iran and selected countries. Journal of New Achievements in Public Law. 2022; (3): 1-22. [In Persian]. Available from: https://www.magiran.com/p2579798
7. Ashrafi Shahmirzadi N, Abdollahiasl A, Kebriaeezadeh A. Assessment of influential variables in the pricing of locally manufactured pharmaceuticals: current challenging situation in Iran. Iranian Journal of Pharmaceutical Research. 2021; 20(1): 283-95. [DOI:10.22037/ijpr.2020.112288.13662]
8. Tatar M. Short pharmaceutical pricing and reimbursement information (PPRI) pharma profile: Turkey. WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. 2017.
9. Vogler S. Pharmaceutical pricing and reimbursement information (PPRI) pharma briefs: Spain. Commissioned by the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection. 2020.
10. Vogler S. Pharmaceutical pricing and reimbursement information (PPRI) pharma briefs: France. Commissioned by the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection. 2020.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Site Keywords
Health, Administration, Scientific Article, Iran University of Medical Sciences,
